NCT00512265View on ClinicalTrials.gov

Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

January 31, 2009

Conditions
Pulmonary Morbidity
Interventions
DRUG

n-acetylcysteine

150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3

DRUG

250mL glucose 5%

placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3

Trial Locations (2)

Unknown

University Hospital Basel, Basel

Department of Surgery, Triemli Hospital, Zurich, Switzerland, Zurich

All Listed Sponsors
collaborator

Triemli Hospital

OTHER

lead

University Hospital, Basel, Switzerland

OTHER

NCT00512265 - Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer | Biotech Hunter | Biotech Hunter